Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Karyopharm Therapeutics Has a Unique Growth Opportunity

By Amar Khatri - Feb 26, 2020 at 9:09AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This cancer-drug maker has a novel medicine with the possibility for extraordinary growth.

Cancer-drug maker Karyopharm Therapeutics (KPTI 4.88%) has seen phenomenal growth since early 2019, with its stock up more than 60% in a bit more than a year.

The 12-year-old company is pioneering novel drugs that will help treat patients with certain blood cancers or solid tumors. Over the past six months alone, the stock has generated gains of 72%. So what's generating all this buzz?

Blood Cancer


Novel drug, huge opportunity

A key area of focus for Karyopharm is the blood cancer known as multiple myeloma (MM). The second most common blood cancer next to non-Hodgkin lymphoma, MM affects the body by taking over healthy blood cells, overwhelming it to the point that it's unable to fight infections.

In July, Karyopharm Therapeutics achieved a milestone with a U.S. Food and Drug Administration (FDA) approval of its treatment for a relapsed or refractory multiple myeloma. This type of cancer is resistant to five of the most commonly used anti-myeloma drugs on the market (Revlimid, Velcade, Poalmyst, Darzalex, and Kyprolis); Karyopharm's drug selinexor, branded as Xpovio, is the first and only medicine that will treat it.

The market researchers at iHealthcareAnalyst expect the market for MM treatments to be huge, anticipating that it may reach $50.5 billion worldwide by 2025. That's an expected compound annual growth rate of 13.3%, driven by branded drugs and potential therapies. MM drugs boast among the highest sales in North America, and global sales were valued at $11.9 billion in 2017, suggesting there is still lots of room to grow in this space. 

Versus the competitors

The leaders in the multiple myeloma space as of 2017 (by sales) include Bristol-Myers Squibb (BMY -0.21%), Takeda Pharmaceuticals (TAK 0.36%), Johnson & Johnson (JNJ 1.13%), and Amgen (AMGN 0.93%)


Sales Rank, 2017

Forecasted Sales, 2017 through 2026 (in Billions)

Bristol-Myers Squibb* -- Revlimid



Takeda/Johnson & Johnson --Velcade



Bristol Myers Squibb* -- Pomalyst



Johnson & Johnson -- Darzalex



Amgen/Ono (Japan) -- Kyprolis



Source: Datamonitor Healthcare
*formerly Celgene 

Bristol-Myers Squibb's Revlimid, the blockbuster drug in MM, has benefited from its important place in multiple myeloma treatment regimens for patients worldwide. Revlimid is different from its competitors because it is taken orally and can be combined with other treatments, and it helped propel Bristol-Meyers Squibb to more than $1 billion in revenue per quarter in 2019.

So if Revlimid is the market leader, where does Karyopharm fit in? 

Xpovio (selinexor) is projected to reach $746 million in sales by 2026 according to market research company PharmaIntelligence, which has projected it would rank sixth in sales by then thanks to a loss of patent exclusivity for many of the top sellers -- including Revlimid -- by 2022. As these drugs start to lose exclusivity, their sales will decline, allowing Karyopharm to take a commanding lead in the market.

Competitive advantages

Xpovio has an advantage in its capability to treat very severe forms of MM. There are no generics or therapeutic equivalents available in the United States, and Karyopharm will enjoy market exclusivity until 2026 and patent exclusivity until 2032. This will allow the company to generate some market share, and it gives time for the study of the drug's usefulness in additional treatments for other forms of cancer. 

In fact, Xpovio was recently approved by the FDA to treat another form of severe cancer called relapsed/refractory diffuse large B-cell lymphoma. This expansion should bring additional revenue for Karyopharm -- and a stock-price increase for shareholders.

Where's it headed?

Since the FDA approval of Xpovio in July, Karyopharm's stock price has exploded, with the help of positive earnings results over the past two quarters. Karyopharm generated more than $30.5 million in net revenue in full-year 2019, with $17.7 million coming in the fourth quarter alone. Prescription demand for Xpovio also saw a boost in the fourth quarter, up 65% compared with the third.

KPTI Chart

KPTI data by YCharts.

This year, Karyopharm will be starting five additional clinical trials using Xpovio to address cancers such as diffuse large B-cell lymphoma, colorectal and lung cancer, glioblastoma (an aggressive form of brain cancer), and myelodysplastic syndromes (MDS). Their success would mean significant growth opportunities for biotech investors in Karyopharm Therapeutics. With $265.8 million in cash, the company has the opportunity to invest in future growth and R&D. The success of Xpovio is making Karyopharm's future look bright. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Karyopharm Therapeutics Inc. Stock Quote
Karyopharm Therapeutics Inc.
$4.73 (4.88%) $0.22
Johnson & Johnson Stock Quote
Johnson & Johnson
$179.52 (1.13%) $2.01
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$76.84 (-0.21%) $0.16
Amgen Inc. Stock Quote
Amgen Inc.
$245.55 (0.93%) $2.25
Takeda Pharmaceutical Company Limited Stock Quote
Takeda Pharmaceutical Company Limited
$14.09 (0.36%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.